Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia

Despite therapeutic advances, mortality of Acute Myeloid Leukemia (AML) is still high. Currently, the determination of prognosis which guides treatment decisions mainly relies on genetic markers. Besides molecular mechanisms, the ability of malignant cells to evade immune surveillance influences the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconato, Maddalena, Kauer, Joseph, Salih, Helmut R., Märklin, Melanie, Heitmann, Jonas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508266/
https://www.ncbi.nlm.nih.gov/pubmed/36151238
http://dx.doi.org/10.1038/s41598-022-19972-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508266/
https://www.ncbi.nlm.nih.gov/pubmed/36151238
http://dx.doi.org/10.1038/s41598-022-19972-1

Ejemplares similares